Your browser doesn't support javascript.
loading
Patterns of Sequelae in Women with a History of Localized Breast Cancer: Results from the French VICAN Survey.
Delrieu, Lidia; Bouaoun, Liacine; Fatouhi, Douae El; Dumas, Elise; Bouhnik, Anne-Deborah; Noelle, Hugo; Jacquet, Emmanuelle; Hamy, Anne-Sophie; Coussy, Florence; Reyal, Fabien; Heudel, Pierre-Etienne; Bendiane, Marc-Karim; Fournier, Baptiste; Michallet, Mauricette; Fervers, Béatrice; Fagherazzi, Guy; Pérol, Olivia.
Afiliação
  • Delrieu L; Department Prevention, Cancer, Environment, Léon Bérard Cancer Center, 69008 Lyon, France.
  • Bouaoun L; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France.
  • Fatouhi DE; International Agency for Research on Cancer, 69372 Lyon, France.
  • Dumas E; Center of Research in Epidemiology and Population Health, UMR 1018 Inserm, Institut Gustave Roussy, Paris-Sud Paris-Saclay University, 94807 Villejuif, France.
  • Bouhnik AD; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France.
  • Noelle H; MINES ParisTech, PSL Research University, CBIO-Centre for Computational Biology, 75006 Paris, France.
  • Jacquet E; INSERM, IRD, SESSTIM, Economics & Social Sciences Applied to Health & Analysis of Medical Information, Aix Marseille University, 13007 Marseille, France.
  • Hamy AS; Department Prevention, Cancer, Environment, Léon Bérard Cancer Center, 69008 Lyon, France.
  • Coussy F; Oncology and Blood Diseases Department, University Hospital Center, Joseph Fourier University, CEDEX 9, 38043 Grenoble, France.
  • Reyal F; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France.
  • Heudel PE; Department of Medical Oncology, Institut Curie, 75005 Paris, France.
  • Bendiane MK; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France.
  • Fournier B; Department of Medical Oncology, Institut Curie, 75005 Paris, France.
  • Michallet M; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Institut Curie, Paris University, 75005 Paris, France.
  • Fervers B; Department of Surgical Oncology, Institut Curie, University Paris, 75005 Paris, France.
  • Fagherazzi G; Department of Medical Oncology, Léon Bérard Cancer Center, 69008 Lyon, France.
  • Pérol O; INSERM, IRD, SESSTIM, Economics & Social Sciences Applied to Health & Analysis of Medical Information, Aix Marseille University, 13007 Marseille, France.
Cancers (Basel) ; 13(5)2021 Mar 08.
Article em En | MEDLINE | ID: mdl-33800346
ABSTRACT
Breast cancer (BC) remains complex for women both physically and psychologically. The objectives of this study were to (1) assess the evolution of the main sequelae and treatment two and five years after diagnosis in women with early-stage breast cancer, (2) explore patterns of sequelae associated with given sociodemographic, clinical, and lifestyle factors. The current analysis was based on 654 localized BC patients enrolled in the French nationwide longitudinal survey "vie après cancer" VICAN (January-June 2010). Information about study participants was collected at enrollment, two and five years after diagnosis. Changes over time of the main sequelae were analyzed and latent class analysis was performed to identify patterns of sequelae related to BC five years after diagnosis. The mean age (±SD) of study participants at inclusion was 49.7 (±10.5) years old. Six main classes of sequelae were identified two years and five years post-diagnosis (functional, pain, esthetic, fatigue, psychological, and gynecological). A significant decrease was observed for fatigue (p = 0.03) and an increase in cognitive sequelae was reported (p = 0.03). Two latent classes were identified-functional and esthetic patterns. Substantial sequelae remain up to five years after BC diagnosis. Changes in patient care pathways are needed to identify BC patients at a high risk.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: França